liver cirrhosis/cannabis

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 46 rezilta yo

Endocannabinoids anandamide and its cannabinoid receptors in liver fibrosis after murine schistosomiasis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This study examined endogenous cannabinoid (ECB)-anandamide (AEA) and its cannabinoid receptors (CBR) in mice liver with the development of schistosoma japonicum. Mice were infected with schistosoma by means of pasting the cercaria onto their abdomens. Liver fibrosis was pathologically confirmed

Cannabinoid receptor-1 antagonism: a new perspective on treating a murine schistosomal liver fibrosis model.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Formation of schistosomal granulomata surrounding the ova can result in schistosomiasis-associated liver fibrosis (SSLF). The current standard of treatment is praziquantel (PZQ), which cannot effectively reverse SSLF. The role of the cannabinoid (CB) receptor family in liver fibrosis

Cannabinoid receptors are involved in the protective effect of a novel curcumin derivative C66 against CCl4-induced liver fibrosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Liver fibrosis is one of the major causes of morbidity and mortality worldwide and lacks efficient therapy. Recent studies suggest the curcumin protects liver from fibrosis. However, curcumin itself is in low bioavailable concentration when administered orally, and the protective mechanism remains

Use of cannabis and risk of advanced liver fibrosis in patients with chronic hepatitis C virus infection: A systematic review and meta-analysis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Chronic hepatitis C virus (HCV) infection is one of the most common chronic liver diseases. Several risk factors for the progression of liver fibrosis among these patients have been identified. Use of cannabis could be another risk factor, but the results from epidemiological studies

Marijuana Use Is Not Associated With Progression to Advanced Liver Fibrosis in HIV/Hepatitis C Virus-coinfected Women.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Marijuana (hereafter "tetrahydrocannabinol [THC]") use has been associated with liver fibrosis progression in retrospective analyses of patients with chronic hepatitis C (HCV). We studied long-term effects of THC on fibrosis progression in women coinfected with human immunodeficiency virus (HIV)/HCV

Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Liver fibrosis, a consequence of chronic liver injury and a way station to cirrhosis and hepatocellular carcinoma, lacks effective treatment. Endocannabinoids acting via cannabinoid-1 receptors (CB1R) induce profibrotic gene expression and promote pathologies that predispose to liver fibrosis. CB1R

Cannabinoid receptor type I modulates alcohol-induced liver fibrosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The cannabinoid system (CS) is implicated in the regulation of hepatic fibrosis, steatosis and inflammation, with cannabinoid receptors 1 and 2 (CB1 and CB2) being involved in regulation of pro- and antifibrogenic effects. Daily cannabis smoking is an independent risk factor for the progression of

Curcumin modulates cannabinoid receptors in liver fibrosis in vivo and inhibits extracellular matrix expression in hepatic stellate cells by suppressing cannabinoid receptor type-1 in vitro.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Activation of hepatic stellate cells (HSCs) is a pivotal event leading to extracellular matrix (ECM) overproduction during hepatic fibrogenesis. Compelling evidence indicates that cannabinoid receptors (CBRs) play an important role in chronic liver disease. Antagonism of hepatic CBR type 1 (CBR1)

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Hepatic fibrosis, the common response associated with chronic liver diseases, ultimately leads to cirrhosis, a major public health problem worldwide. We recently showed that activation of hepatic cannabinoid CB2 receptors limits progression of experimental liver fibrosis. We also found that during

Endogenously produced cannabinoids and liver cirrhosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

[Expression of cannabinoid receptors in hepatic stellate cells of patients with chronic hepatitis B and significance for progression of liver fibrosis].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

[The expression of cannabinoid receptor 1 in liver tissue of chronic hepatitis B patients involved in liver fibrosis].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

[Blockage of the CB1 cannabinoid receptor for the prevention of liver cirrhosis ].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We report the design, synthesis, and structure-activity relationships of novel dual-target compounds with antagonist/inverse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory effect on inducible nitric oxide synthase (iNOS). A series of 3,4-diarylpyrazolinecarboximidamides were

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye